The purpose of this multi-national disease registry is to collect prospectively (with
longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture
changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over
time.
The registry will capture data on participants; demographic, clinical characteristics
(including biomarker data), treatment patterns, and effectiveness and safety outcomes for
advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants
treated with systemic therapy.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05376891.
Locations matching your search criteria
United States
Ohio
Columbus
Ohio State University Comprehensive Cancer CenterStatus: Active
Name Not Available
This is a disease registry, which is an organized system using non-interventional methods
to collect data on a patient population defined by a particular disease, exposure, or
condition, and which is followed over time. Non-interventional means that after
participants enrollment, participants will be treated according to the routine clinical
treatment decision by the physician. The registry will not impose any treatment or
procedure for participants.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationEMD Serono Research & Development Institute, Inc.
